Abstracts tagged "Diagnostic Tests"

Abstract Number: 2075 • 2016 ACR/ARHP Annual Meeting
No Detection of Varicella-Zoster Virus in Temporal Arteries of Patients with Giant Cell Arteritis
Francesco Muratore¹, Stefania Croci², Ione Tamagnini³, Alessandro Zerbini², Salvatore Bellafiore⁴, Lucia Belloni⁵, Luigi Boiardi⁶, Alessandra Bisagni⁷, Maria Parmeggiani⁸, Alberto Cavazza⁹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Clinical Immunology, Allergy and Advanced Biotechnologies Unit,, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³Pathology Unit, Department of Oncology, Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Pathology Unit, Department of Oncology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁷Pathology Unit, Department of Oncology, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁸. Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁹Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Recent studies found an high prevalence of varicella-zoster virus (VZV) infection in temporal arteries (TAs) from both temporal artery biopsy (TAB)-positive and TAB-negative giant…
Abstract Number: 2800 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus
James Mossell¹, John A. Goldman², Derren Barken³ and Roberta Alexander⁴, ¹Tift Regional Medical Center, Tifton, GA, ²Medical Quarters #293, Emory St. Joseph’s Hospital, Atlanta, GA, ³Exagen Diagnostics, Vista, CA, ⁴Research & Development, Exagen Diagnostics, Vista, CA
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are sensitive and specific biomarkers in the differential diagnosis of systemic lupus erythematosus (SLE) and other rheumatic diseases, as…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 3106 • 2016 ACR/ARHP Annual Meeting
A Simple Test for Assessing and Monitoring SLE Disease Activity Status
Chaim Putterman¹, Michael Rowe², Joseph Barten Legutki², Theodore M. Tarasow² and Kathryn Sykes², ¹Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ²HealthTell, Inc, san ramon, CA
Background/Purpose: SLE patients can experience chronically active disease, remissions and flares, or long periods of quiescence. Accurately assessing disease activity is crucial for prescribing appropriate…
Abstract Number: 218 • 2016 ACR/ARHP Annual Meeting
Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture
Stephanie Fabre¹, Jean-Marie Launay¹, Jean-François Gautier¹, Adam Platt², Jeffrey N. Miner³, Glen Hughes², Pascal Richette⁴ and Thomas Bardin¹, ¹Hôpital Lariboisière, Paris, France, ²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁴Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: A key factor in the success of gout management is the long-term lowering of serum uric acid (sUA) levels below predetermined targets (5 or…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 512 • 2016 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons
Yoichiro Haji¹, Ryo Rokutanda², Mitsumasa Kishimoto² and Masato Okada², ¹Rheumatology, Daido Hospital, Nagoya, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: To evaluate anti-cyclic citrullinated protein antibody positivity in the general population and to identify its prognosis. Methods: Anti-cyclic citrullinated protein antibody (ACPA) were measured…
Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…
Abstract Number: 2190 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA)
Maria Laura Bertolaccini¹, Danieli Andrade², Gabriella Lakos³, Rohan Willis⁴, Vittorio Pengo⁵, Alessandra Banzato⁶, Hannah Cohen⁷, Steven Krilis⁸, Doruk Erkan⁹ and on behalf of APS ACTION, ¹Lupus Unit, Rayne Institute, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³INOVA Diagnostics, Inc., San Diego, CA, ⁴Department of Internal Medicine, Antiphospholipid Standardization Laboratory, Division of Rheumatology, Galveston, TX, ⁵Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁶Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁷Hematology., University College London, LOndon, United Kingdom, ⁸Immunology, Allergy, and Infectious Diseases, St George Hospital, Kogarah NSW, Australia, ⁹Rheumatology, Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently aPL-positive patients with/without…
Abstract Number: 2231 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency States Can be Actively Prevented. Results from a Cross-Sectional Study of over 3000 Patients with Rheumatic Diseases
Elena Nikiphorou¹, Pekka Hannonen¹, Paula Väre¹, Arto Kokko², Tuomas Rannio^3,4 and Tuulikki Sokka-Isler⁴, ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Kuopio University Hospital, Kuopio, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Vitamin D (D25) deficiency has been an ongoing matter of concern, especially in countries at northern latitudes. The effects of D25 deficiency in patients…
Abstract Number: 2598 • 2015 ACR/ARHP Annual Meeting
Neutrophil Extracellular Trap Levels Measured By Cell Free Nucleosome ELISA in Serum Are Highly Specific and Sensitive for Rheumatoid Arthritis
Paul Hasler¹, Stavros Giaglis¹, Ulrich A. Walker², Erik Deman¹, Christoph Hemmeler¹, Christina Ryser¹, Samuel Kretzschmar¹, Guenther Schaefer³, Juliane Franz¹ and Sinuhe Hahn⁴, ¹Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ²Rheumatology, University Hospital, Basel, Basel, Switzerland, ³Dept. of Biomedicine, Laboratory of Prenatal Medicine, University Hospital Basel, Basel, Switzerland, ⁴Dept. of Biomedicine, Laboratory for Prenatal Medicine, University Hospital Basel, Basel, Switzerland
Background/Purpose: Rheumatoid factor (RF) or anti-citrullinated peptide antibody (ACPA) detection have limited clinical utility for the diagnosis of rheumatoid arthritis (RA), as the specificity and…
Abstract Number: 2614 • 2015 ACR/ARHP Annual Meeting
Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis
Lance Feller¹, Paul Tuttle IV², Austin M. Dalrymple³, Srikanth Bathula⁴, Katherine Temprano⁵, Reema H. Syed⁶, Rama Bandlamudi⁷, Kathryn Coulson⁸, Peri Pepmueller⁹ and Terry Moore¹⁰, ¹Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO, ²Saint Louis University, Saint Louis, MO, ³Pediatric Rheumatology, St. Louis University, St. Louis, MO, ⁴Rheumatology, Saint Louis University, Saint Louis, MO, ⁵Medicine/Rheumatology, Saint Louis University, St. Louis, MO, ⁶IM-Rheumatology, Saint Louis University, St. Louis, MO, ⁷Internal Medicine/Rheumatology, St. Louis Univ Health Sciences, St. Louis, MO, ⁸Rheumatology/ 213A, St. Louis University, St. Louis, MO, ⁹Rheumatology, Saint Louis University, St. Louis, MO, ¹⁰Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 101 • 2015 ACR/ARHP Annual Meeting
New Technologies for Typing Self-Identifying Antigens Encoded By HLA Genes Provide Cost-Effective Alternatives to Identifying B27 Allele Status in Rheumatoid Arthritis Subjects
Kimberly Robasky¹, Jatinder Kaur², Jennifer Sims¹, Melissa Howard¹, Eric Earley¹ and Eric Lai², ¹EA|Quintiles, Durham, NC, ²Takeda Pharmaceuticals International, Inc., Deerfield, IL
Background/Purpose: Human leukocyte antigen (HLA) genes code for proteins that allow the immune system to distinguish self from foreign cells. These genes have important indications…
Abstract Number: 2617 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis
Olga S. Zhukov¹, Jonnielyn G. Rivera¹, Rania W. Abolhosn¹, Robert J. Lagier², Charles M. Rowland³, Joanna M. Popov¹, Kaleb Michaud⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ³Research Support, Quest Diagnostics Alameda, Alameda, CA, ⁴Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank, Omaha, NE
Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].